You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 292 No. 19, November 17, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Correction
 This Article
 •PDF of this Correction
 •Original article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

JAMA. 2004;292:2340.

Financial Disclosure Omitted: In the Preliminary Communication entitled "Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers" published in the July 28, 2004, issue of JAMA (2004;292:462-469), a financial disclosure was omitted. Oregon Health and Science University (OHSU), Drs Gravett, Rosenfeld, Reddy, Jacob, Roberts, and Nagalla and Mr Turner all have a significant financial interest in Proteogenix Inc, a company that may have a commercial interest in the results of this research and technology. Among the 3 investigators involved in statistical analysis of the study (Drs Gravett, Lapidus, and Hitti), the latter 2 have no potential financial interest in the results of this research. This potential conflict of interest has been reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee, and the Integrity Program Oversight Council has been implemented.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.